home / stock / hrow / hrow news


HROW News and Press, Harrow Health Inc. From 03/20/24

Stock Information

Company Name: Harrow Health Inc.
Stock Symbol: HROW
Market: NASDAQ
Website: harrowinc.com

Menu

HROW HROW Quote HROW Short HROW News HROW Articles HROW Message Board
Get HROW Alerts

News, Short Squeeze, Breakout and More Instantly...

HROW - EURN, STI and PUK among pre-market losers

2024-03-20 08:11:18 ET More on pre-market losers & stocks. Prudential: Consider Both Upcoming Results And 2024 Risk Factors Euronav NV: Not Backing Down On The Decarbonization Agenda Euronav NV 2023 Q4 - Results - Earnings Call Presentation Solidion Techn...

HROW - Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M

2024-03-20 01:11:43 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...

HROW - Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of...

HROW - Expected US Company Earnings on Tuesday, March 19th, 2024

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

HROW - Notable earnings after Tuesday's close

2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...

HROW - Harrow Health Q4 2023 Earnings Preview

2024-03-18 17:35:14 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...

HROW - Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tue...

HROW - (HROW) Technical Pivots with Risk Controls

2024-03-02 14:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

HROW - SRK Capital H2 2023 Investor Letter

2024-02-21 11:40:00 ET Summary SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated 17.15% during 2023. I believe our holdings present a significant opportunity with minimal fundamental downside and s...

HROW - Harrow's Drug Iheezo Is Off To A Great Start

2024-02-19 09:30:00 ET Summary Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheezo, initially faced skepticism but has seen signifi...

Previous 10 Next 10